The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...

For the first time, a drug to treat adult patients with familial chylomicronemia syndrome (FCS), a severe and rare condition that leads to extremely high levels of blood fats called triglycerides, has ...

Small interfering RNA (siRNA) drugs are a class of therapeutic agents that silence specific genes associated with inherited diseases. However, siRNA drugs have challenges because siRNAs often silence ...

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and ...

AbbVie is paying ADARx Pharmaceuticals $335 million upfront to secure options on next-gen small interfering RNA (siRNA) therapeutics across several disease areas. The collaboration and license option ...

CHICAGO -- Novel small interfering RNA (siRNA) agent lepodisiran drastically cut levels of lipoprotein(a), or Lp(a), in the phase II ALPACA trial. The 400-mg dose cut Lp(a) by 93.9 percentage points ...

Researchers have designed a smart drug that hunts down and breaks a little-known RNA that cancer cells depend on. The drug recognizes a unique fold in the RNA and triggers the cell to destroy it.

With the question of immunotherapeutics’ efficacy answered in the resounding affirmative, the challenge has shifted to the practical considerations of how to cost-effectively manufacture these highly ...

COVID-19 RNA may induce monocytes to develop cancer-fighting properties, potentially shrinking tumors in certain metastatic cancers. Patients resistant to prior immunotherapy showed the most benefit ...

University of Chicago researchers have developed a liquid biopsy test based on modification patterns in microbiome-derived cell-free RNA that predicts colorectal cancer (CRC) with greater accuracy ...